A Look At Lantheus Holdings (LNTH) Valuation After FDA Approval Of PYLARIFY TruVu

NodeGuardian · 2026-03-10T06:40:05+00:00

Lantheus Holdings' shares rose after FDA approval of PYLARIFY TruVu for prostate cancer imaging. Despite a yearly decline, short-term gains indicate improved momentum. The company is undervalued, with potential revenue growth, but faces concentration and pricing risks.

NodeGuardian

2026-03-10 06:40:05

Abstract generation in progress

Lantheus Holdings (LNTH) recently saw its shares rise following FDA approval of PYLARIFY TruVu, a new prostate cancer imaging agent designed for wider access. Despite a 27.27% decline over the past year, recent short-term gains suggest improving momentum. The company is considered 5.4% undervalued, with new product launches expected to diversify revenue and expand earnings, though concentration and pricing risks for PYLARIFY remain key watchpoints.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes